Cargando…
Mutation status and prognostic value of KRAS and NRAS mutations in Moroccan colon cancer patients: A first report
This study aimed to estimate the incidence of KRAS, NRAS, and BRAF mutations in the Moroccan population, and investigate the associations of KRAS and NRAS gene mutations with clinicopathological characteristics and their prognosis value. To achieve these objectives, we reviewed medical and pathology...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009361/ https://www.ncbi.nlm.nih.gov/pubmed/33784337 http://dx.doi.org/10.1371/journal.pone.0248522 |
_version_ | 1783672858365394944 |
---|---|
author | El agy, Fatima el Bardai, Sanae El Otmani, Ihsane Benbrahim, Zineb Karim, Ibn Majdoub Hassani Mazaz, Khalid Benjelloun, El Bachir Ousadden, Abdelmalek El Abkari, Mohammed Ibrahimi, Sidi Adil Chbani, Laila |
author_facet | El agy, Fatima el Bardai, Sanae El Otmani, Ihsane Benbrahim, Zineb Karim, Ibn Majdoub Hassani Mazaz, Khalid Benjelloun, El Bachir Ousadden, Abdelmalek El Abkari, Mohammed Ibrahimi, Sidi Adil Chbani, Laila |
author_sort | El agy, Fatima |
collection | PubMed |
description | This study aimed to estimate the incidence of KRAS, NRAS, and BRAF mutations in the Moroccan population, and investigate the associations of KRAS and NRAS gene mutations with clinicopathological characteristics and their prognosis value. To achieve these objectives, we reviewed medical and pathology reports for 210 patients. RAS testing was investigated by Sanger sequencing and Pyrosequencing technology. BRAF (exon 15) status was analyzed by the Sanger method. The expression of MMR proteins was evaluated by Immunohistochemistry. KRAS and NRAS mutations were found in 36.7% and 2.9% of 210 patients, respectively. KRAS exon 2 mutations were identified in 76.5% of the cases. RAS-mutated colon cancers were significantly associated with female gender, presence of vascular invasion, classical adenocarcinoma, moderately differentiated tumors, advanced TNM stage III-IV, left colon site, higher incidence of distant metastases at the time of diagnostic, microsatellite stable phenotype, lower number of total lymph nodes, and higher means of positive lymph nodes and lymph node ratio. KRAS exon 2-mutated colon cancers, compared with KRAS wild-type colon cancers were associated with the same clinicopathological features of RAS-mutated colon cancers. NRAS-mutated patients were associated with lower total lymph node rate and the presence of positive lymph node. Rare RAS-mutated tumors, compared with wild-type tumors were more frequently moderately differentiated and associated with lower lymph node rate. We found that KRAS codon 13-mutated, tumors compared to codon 12-mutated tumors were significantly correlated with a higher death cases number, a lower rate of positive lymph, lower follow-up time, and poor overall survival. Our findings show that KRAS and NRAS mutations have distinct clinicopathological features. KRAS codon 13-mutated status was the worst predictor of prognosis at all stages in our population. |
format | Online Article Text |
id | pubmed-8009361 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-80093612021-04-07 Mutation status and prognostic value of KRAS and NRAS mutations in Moroccan colon cancer patients: A first report El agy, Fatima el Bardai, Sanae El Otmani, Ihsane Benbrahim, Zineb Karim, Ibn Majdoub Hassani Mazaz, Khalid Benjelloun, El Bachir Ousadden, Abdelmalek El Abkari, Mohammed Ibrahimi, Sidi Adil Chbani, Laila PLoS One Research Article This study aimed to estimate the incidence of KRAS, NRAS, and BRAF mutations in the Moroccan population, and investigate the associations of KRAS and NRAS gene mutations with clinicopathological characteristics and their prognosis value. To achieve these objectives, we reviewed medical and pathology reports for 210 patients. RAS testing was investigated by Sanger sequencing and Pyrosequencing technology. BRAF (exon 15) status was analyzed by the Sanger method. The expression of MMR proteins was evaluated by Immunohistochemistry. KRAS and NRAS mutations were found in 36.7% and 2.9% of 210 patients, respectively. KRAS exon 2 mutations were identified in 76.5% of the cases. RAS-mutated colon cancers were significantly associated with female gender, presence of vascular invasion, classical adenocarcinoma, moderately differentiated tumors, advanced TNM stage III-IV, left colon site, higher incidence of distant metastases at the time of diagnostic, microsatellite stable phenotype, lower number of total lymph nodes, and higher means of positive lymph nodes and lymph node ratio. KRAS exon 2-mutated colon cancers, compared with KRAS wild-type colon cancers were associated with the same clinicopathological features of RAS-mutated colon cancers. NRAS-mutated patients were associated with lower total lymph node rate and the presence of positive lymph node. Rare RAS-mutated tumors, compared with wild-type tumors were more frequently moderately differentiated and associated with lower lymph node rate. We found that KRAS codon 13-mutated, tumors compared to codon 12-mutated tumors were significantly correlated with a higher death cases number, a lower rate of positive lymph, lower follow-up time, and poor overall survival. Our findings show that KRAS and NRAS mutations have distinct clinicopathological features. KRAS codon 13-mutated status was the worst predictor of prognosis at all stages in our population. Public Library of Science 2021-03-30 /pmc/articles/PMC8009361/ /pubmed/33784337 http://dx.doi.org/10.1371/journal.pone.0248522 Text en © 2021 El agy et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article El agy, Fatima el Bardai, Sanae El Otmani, Ihsane Benbrahim, Zineb Karim, Ibn Majdoub Hassani Mazaz, Khalid Benjelloun, El Bachir Ousadden, Abdelmalek El Abkari, Mohammed Ibrahimi, Sidi Adil Chbani, Laila Mutation status and prognostic value of KRAS and NRAS mutations in Moroccan colon cancer patients: A first report |
title | Mutation status and prognostic value of KRAS and NRAS mutations in Moroccan colon cancer patients: A first report |
title_full | Mutation status and prognostic value of KRAS and NRAS mutations in Moroccan colon cancer patients: A first report |
title_fullStr | Mutation status and prognostic value of KRAS and NRAS mutations in Moroccan colon cancer patients: A first report |
title_full_unstemmed | Mutation status and prognostic value of KRAS and NRAS mutations in Moroccan colon cancer patients: A first report |
title_short | Mutation status and prognostic value of KRAS and NRAS mutations in Moroccan colon cancer patients: A first report |
title_sort | mutation status and prognostic value of kras and nras mutations in moroccan colon cancer patients: a first report |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009361/ https://www.ncbi.nlm.nih.gov/pubmed/33784337 http://dx.doi.org/10.1371/journal.pone.0248522 |
work_keys_str_mv | AT elagyfatima mutationstatusandprognosticvalueofkrasandnrasmutationsinmoroccancoloncancerpatientsafirstreport AT elbardaisanae mutationstatusandprognosticvalueofkrasandnrasmutationsinmoroccancoloncancerpatientsafirstreport AT elotmaniihsane mutationstatusandprognosticvalueofkrasandnrasmutationsinmoroccancoloncancerpatientsafirstreport AT benbrahimzineb mutationstatusandprognosticvalueofkrasandnrasmutationsinmoroccancoloncancerpatientsafirstreport AT karimibnmajdoubhassani mutationstatusandprognosticvalueofkrasandnrasmutationsinmoroccancoloncancerpatientsafirstreport AT mazazkhalid mutationstatusandprognosticvalueofkrasandnrasmutationsinmoroccancoloncancerpatientsafirstreport AT benjellounelbachir mutationstatusandprognosticvalueofkrasandnrasmutationsinmoroccancoloncancerpatientsafirstreport AT ousaddenabdelmalek mutationstatusandprognosticvalueofkrasandnrasmutationsinmoroccancoloncancerpatientsafirstreport AT elabkarimohammed mutationstatusandprognosticvalueofkrasandnrasmutationsinmoroccancoloncancerpatientsafirstreport AT ibrahimisidiadil mutationstatusandprognosticvalueofkrasandnrasmutationsinmoroccancoloncancerpatientsafirstreport AT chbanilaila mutationstatusandprognosticvalueofkrasandnrasmutationsinmoroccancoloncancerpatientsafirstreport |